Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy

Nguyen-Nielsen, Mary; Liede, Alexander; Mægbæk, Merete Lund; Borre, Michael; Harving, Niels; Hernandez, Rohini K.; Sørensen, Henrik Toft; Ehrenstein, Véra

doi:10.1016/j.canep.2015.05.008

Cited by 11 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, radionuclide bone imaging is commonly used for prostate cancer bone metastasis diagnosis and monitoring with high sensitivity. However, its disadvantages include low specificity, high cost, and the radioactive harm to patients and staff (Luna et al, 2015;Nguyen-Nielsen et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Wei¹,

Li²,

Yang³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Bone metastasis is a common complication in prostate cancer patients that can cause bone pain and pathological fracture. This study tested serum levels of prostate specific antigen (PSA), alkaline phosphatase (ALP), bone sialoprotein (BSP), collagen type I pyridine crosslinking peptide (ICTP) in prostate cancer patients and the significance of the receiver operator characteristic (ROC) curve in the diagnosis of prostate cancer bone metastases. Eighty-three prostate cancer patients were enrolled including 42 in the bone metastases group and 41 in the non-bone metastases group. Serum levels of BSP, ALP, ICTP, and PSA were highest in the bone metastases group followed by the non-bone metastases group, hyperplasia group, and then the control group (P < 0.05). Based on Gleason score, serum levels were highest in the poorly differentiated group followed by moderately differentiated and well-differentiated groups (P < 0.05). ROC curve analysis revealed that the diagnostic efficiency of the biomarkers in turn was BSP, PSA, ICTP, and ALP. The sensitivity of BSP, ALP, ICTP, and PSA in the diagnosis of prostate cancer bone metastases were 80.95, 57.14, 69.05, 71.43%, respectively, and the specificity of the same markers were 72. 80, 64.80, 76.80, and 88.80%, respectively. Combined detection of the four markers improved sensitivity to 97.62% and the negativepredictive value increased to 97.60%. PSA + BSP showed the best efficiency when combining two markers. In conclusion, serum levels of BSP, ALP, ICTP, and PSA increased in patients with bone metastases, and combined detection of all markers could improve the positivepredictive value.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Wei¹,

Li²,

Yang³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…PSA‐DT is a well‐used study variable in both clinical and epidemiological studies already published. 18 , 19 Moreira et al found in two retrospective analyses in men with nmCRPC ( n = 458) and mCRPC ( n = 205) that shorter PSA‐DT and higher PSA at the date of CRPC diagnosis were significantly associated with shorter time to metastasis and shorter OS. 20 , 21 Other biomarkers such as circulating tumor cells (CTCs) have shown to be superior to PSA kinetics in predicting the outcome for CRPC patients, 22 but such information is lacking in the present data.…”

Section: Discussionmentioning

confidence: 99%

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

et al. 2021

View full text Add to dashboard Cite

Objectives: The objective of this study is to find clinical variables that predict the prognosis for men with castration-resistant prostate cancer (CRPC) in a Swedish reallife CRPC cohort, including a risk group classification to clarify the risk of succumbing to prostate cancer. This is a natural history cohort representing the premodern drug era before the introduction of novel hormonal drug therapies.Methods: PSA tests from the clinical chemistry laboratories serving health care in six regions of Sweden were retrieved and cross-linked to the National Prostate Cancer Registry (NPCR) to identify men with a prostate cancer diagnosis. Through further cross-linking with data sources at the Swedish Board of Health and Welfare, we retrieved other relevant information such as prescribed drugs, hospitalizations, and cause of death. Men entered the CRPC cohort at the first date of doubling of their PSA nadir value with the last value being >2 ng/ml, or an absolute increase of >5 ng/ml or more, whilst on 3 months of medical castration or if they had been surgically castrated (n = 4098). By combining the two variables with the largest C-statistics, "PSA at time of CRPC" and "PSA doubling time," a risk group classification was created.Results: PSA-DT and PSA at date of CRPC are the strongest variables associated with PC specific survival. At the end of follow-up, the proportion of men who died due to PC was 57%, 71%, 81%, 86%, and 89% for risk categories one through five, respectively. The median overall survival in our cohort of men with CRPC was 1.86 years (95% CI: 1.79-1.97). Conclusion:For a man with castration-resistant prostate cancer, there is a high probability that this will be the main cause contributing to his death. However, there is a significant difference in mortality that varies in relation to tumor burden assessed as PSA doubling time and PSA at time of CRCP. This information could be used in a clinical setting when deciding when to treat more or less aggressively once entering the CRPC phase of the disease.

show abstract

“…Após o sucesso inicial desses compostos, vários outros fármacos antitumorais foram desenvolvidos. Além dessas, outras abordagens farmacológicas têm sido utilizadas: a terapia alvo-direcionada, tais como a hormonioterapia e a imunoterapia comumente combinada com agentes citotóxicos (CARNEIRO et al, 2015;NGUYEN-NIELSEN et al, 2015).…”

Section: Introductionunclassified

Potenciais Alvos Terapêuticos Para O Tratamento Do Câncer

Pedrosa¹

2020

Saúde Pública No Século Xxi: Uma Abordagem Sobre Ciências Farmacêuticas

View full text Add to dashboard Cite

Desde os primórdios da humanidade, quando os nossos ancestrais começaram a observar os efeitos biológicos das plantas, já havia nesse comportamento empírico, um embrião que viria a se chamar farmacologia. Essa ciência, que tem seu inicio misturado com a história da terapêutica, é considerada como tal, desde o século XIX. E é inegável sua contribuição para o aumento da expectativa de vida de nossa espécie, bem como dos animais domésticos. Em menos de um século de seu status de ciência, se apresenta como base da conhecida indústria farmacêutica, que muitas vezes é colocada como ré da exploração dos enfermos por meio de ganhos vultuosos. Mas a face dessa ciência que poucos conhecem e que não é noticiada, forma-se de um grupo de abdicados estudantes e pesquisadores que pensam no melhor para o seu próximo. Nesse livro, os leitores lerão as contribuições, que embora pequenas, se somam a muitas outras para que neste século tenhamos uma saúde melhor para todos.Em nossos livros selecionamos um dos capítulos para premiação como forma de incentivo para os autores, e entre os excelentes trabalhos selecionados para compor este livro, o premiado foi o capítulo 2, intitulado "Adesão ao tratamento farmacológico em pacientes com insuficiência renal crônica ".

show abstract

Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy

Cited by 11 publications

References 24 publications

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

Potenciais Alvos Terapêuticos Para O Tratamento Do Câncer

Contact Info

Product

Resources

About